Seeking Alpha

Cempra (CEMP -0.2%) fails to get any reaction out of Jefferies' initiating coverage today with a...

Cempra (CEMP -0.2%) fails to get any reaction out of Jefferies' initiating coverage today with a Buy rating and $10 price target. The firm cites optimism over its pipeline, saying that its lead drug solithromycin is the key value driver. However, the company has limited capital, which has impacted its ability to conduct Phase 3 trials in an expedited manner. It will likely need to secure additional financing to further advance its programs, leaving the the stock with a potential dilutive overhang.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)